WEZLANA Drug Profile

Summary for Tradename: WEZLANA

High Confidence Patents:	0
Applicants:	1
BLAs:	2

Pharmacology for WEZLANA

Mechanism of Action	Interleukin-12 Antagonists Interleukin-23 Antagonists
Established Pharmacologic Class	Interleukin-12 Antagonist Interleukin-23 Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for WEZLANA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for WEZLANA Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for WEZLANA Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for WEZLANA

Last updated: April 15, 2026

What is WEZLANA?

WEZLANA (generic name: bemarituzumab) is a monoclonal antibody targeting fibroblast growth factor receptor 2b (FGFR2b). It is developed by Five Prime Therapeutics, now part of Zentalis Pharmaceuticals. The drug is administered via intravenous infusion and is aimed at treating advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Market Opportunity and Context

Key Indications

• Gastric and GEJ adenocarcinoma
• FGFR2b overexpression in approximately 10-15% of gastric cancers

Competitive Landscape

• Traditionally dominated by chemotherapy
• Few targeted therapies approved for FGFR2b-positive gastric cancers
• Leading competitors include drugs like HER2-targeting trastuzumab and immune checkpoint inhibitors (e.g., pembrolizumab)

Regulatory Status

• Phase 2 trial results published in 2021 demonstrated promising efficacy
• FDA breakthrough therapy designation granted in April 2022
• JalView trial initiation in 2022 to evaluate efficacy in combination with chemotherapy

Financial Trajectory

R&D Funding and Costs

• Initial funding from Five Prime totaled approximately $250 million before acquisition
• R&D expenses in 2022 reported at $55 million, high relative to revenue
• Investment largely directed towards clinical trial phases, especially Phase 2 and upcoming Phase 3 studies

Revenue Streams

• As of 2023, WEZLANA has not generated commercial revenue
• Revenue dependent on regulatory approvals and successful commercialization

Market Penetration and Sales Projections

• Estimated addressable market size: 70,000-80,000 new cases globally annually
• Targeted adoption in U.S., EU, Japan, and South Korea
• Estimated peak annual sales: USD 1 billion if approved and widely adopted, based on FDA approval assumptions and competitive positioning

Pricing and Reimbursement

• Approximated annual treatment cost: USD 150,000 - 200,000 per patient
• Reimbursement likely through national healthcare systems and private insurers
• Pricing will influence adoption speed, especially in markets with stringent cost-effectiveness thresholds

Key Financial Milestones

Milestone	Estimated Timeline	Market Impact
Phase 2 trial data publication	2021	Validates efficacy, increases investor confidence
FDA breakthrough designation	April 2022	Accelerates development timeline, boosts valuation
Initiation of Phase 3 trial	2023	Critical for commercial approval prospects
Anticipated NDA submission	2024	Major inflection point, potential revenue flow

Market Trends and Risks

Trends

• Rising incidence of gastric cancer in East Asia
• Increasing adoption of targeted therapies and personalized medicine
• International expansion plans focusing on Asian markets with high prevalence

Risks

• Competition from other FGFR2b-targeting agents or broader targeted therapies
• Challenges in clinical trial outcomes—failure could delay approval
• Pricing pressures in developed markets, potentially limiting profitability

Key Takeaways

• WEZLANA targets a niche but significant segment of gastric cancer patients with FGFR2b overexpression.
• As of 2023, the drug is in late-stage clinical development with potential FDA approval imminent.
• Financially, the product's success hinges on achieving regulatory approval, market access, pricing, and reimbursement strategies.
• The therapy's commercial outlook depends heavily on clinical trial outcomes and global adoption in high-incidence regions.

FAQs

1. When is WEZLANA expected to receive FDA approval?
Potential approval may occur by 2024, contingent on successful Phase 3 trial results and regulatory review.

2. What is the competitive advantage of WEZLANA?
It specifically targets FGFR2b in gastric cancers, an indication with limited targeted therapy options and high unmet need.

3. How much could WEZLANA generate in sales?
Peaking around USD 1 billion annually if approved and adopted broadly in key markets.

4. What are the main risks associated with WEZLANA’s market entry?
Clinical trial failures, competition from alternative treatments, and pricing constraints.

5. How is the global gastric cancer market evolving?
Incidence rises, especially in Asia; adoption of personalized treatments increases, with new targeted therapies like WEZLANA contributing to growth.

---

References

1. Zentalis Pharmaceuticals. (2022). Clinical trial updates on WEZLANA. [4]
2. FDA. (2022). Breakthrough therapy designation for bemarituzumab. [1]
3. Globocan. (2022). Cancer incidence and mortality data. [2]
4. Five Prime Therapeutics. (2021). Phase 2 clinical trial results. [3]